Dengue fever future or investigational therapies: Difference between revisions
| Line 6: | Line 6: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Emerging evidence suggests that [[mycophenolic acid]] and [[ribivirin]] inhibit dengue replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.<sup>[http://vir.sgmjournals.org/cgi/content/full/87/7/1947]</sup> ''In vivo'' studies, however, have not yet been done. | Emerging evidence suggests that [[mycophenolic acid]] and [[ribivirin]] inhibit dengue replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.<sup>[http://vir.sgmjournals.org/cgi/content/full/87/7/1947]</sup> ''In vivo'' studies, however, have not yet been done. | ||
There are many ongoing vaccine development programs. One is the Pediatric Dengue Vaccine Initiative which was set up in 2003 with the aim of accelerating the development and introduction of dengue vaccine(s) that are affordable and accessible to poor children in endemic countries.[1] Thai researchers are testing a dengue fever vaccine on 3,000-5,000 human volunteers within the next three years after having successfully conducted tests on animals and a small group of human volunteers.[2] and a number of other vaccine candidates are entering phase I or II testing.[3] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 13:47, 8 June 2014
|
Dengue Fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dengue fever future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Dengue fever future or investigational therapies |
|
Dengue fever future or investigational therapies in the news |
|
Risk calculators and risk factors for Dengue fever future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Emerging evidence suggests that mycophenolic acid and ribivirin inhibit dengue replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.[2] In vivo studies, however, have not yet been done.
There are many ongoing vaccine development programs. One is the Pediatric Dengue Vaccine Initiative which was set up in 2003 with the aim of accelerating the development and introduction of dengue vaccine(s) that are affordable and accessible to poor children in endemic countries.[1] Thai researchers are testing a dengue fever vaccine on 3,000-5,000 human volunteers within the next three years after having successfully conducted tests on animals and a small group of human volunteers.[2] and a number of other vaccine candidates are entering phase I or II testing.[3]